Tiziano Barbui

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.

Paola Guglielmelli, Giovanni Barosi, Roberto Marchioli, 2007, Blood.

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Francisco Cervantes, Giovanni Barosi, Viktoriya Stalbovskaya, 2012, The New England journal of medicine.

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

Paola Guglielmelli, Giovanni Barosi, Carmine Tinelli, 2007, Blood.

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.

Francisco Cervantes, Giovanni Barosi, Juergen Thiele, 2013, Blood.